Silviu Itescu, Mesoblast CEO

Mesoblast asks for trad­ing halt as PDU­FA date slides by. What's up?

Every­thing was all lined up for Mesoblast’s Wednes­day PDU­FA date re­gard­ing its acute graft-ver­sus-host dis­ease can­di­date remestem­cel-L, or Ry­on­cil. But with no word in any di­rec­tion on any FDA ac­tions, the biotech is prepar­ing its stock for the de­layed rul­ing.

Mesoblast $MESO has asked the Aus­tralian stock ex­change to place its shares in a trad­ing halt un­til the com­pa­ny can make an an­nounce­ment about the Ry­on­cil re­view. That an­nounce­ment will like­ly come on Mon­day at the lat­est, the com­pa­ny said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.